Why physiology comes first
Many pharmacological interventions activate or block a target largely according to drug exposure. The biological demand for that activity, however, can change across time and physiological state. Applying the same activity in different states is a design choice that can contribute to overshoot, compensation, tolerance, rebound or receptor regulation.
Aeviant investigates whether, where the mechanism permits, a small molecule can retain meaningful dependence on an endogenous signal or biological state. This is a research position used to frame program design, not a validated platform or a claim that one mechanism applies to every target.
Selectivity in context
Molecular affinity and receptor-subtype preference are necessary parts of drug selectivity, but they do not establish where activity occurs, under which biological conditions it is expressed, or which physiological functions are affected.
Aeviant therefore considers target, state, timing, signalling bias, endogenous demand and functional consequence alongside molecular pharmacology. This framework guides how Aeviant defines a research question; it is not a claim that physiological selectivity has been achieved in any program.
From hypothesis to evidence
The research asks what breaks earliest in a dysregulated cascade and whether restoring that upstream control can be more direct than blocking a later node with parallel inputs. Literature review and computational target characterization are used to define and challenge a testable hypothesis.
Computational output is used for hypothesis generation and prioritization. It is not proof that a molecule binds, produces the intended pharmacology or works in a living system. Aeviant treats computational predictions as questions to test, not experimental results.
Program decisions
A program advances only if predefined criteria survive experimental testing. Reproducible pharmacology, chemical tractability, exposure and safety are considered together rather than as independent claims of progress.
No program is protected from evidence that contradicts its starting model. Failure of a pre-registered criterion is a reason to redirect or stop the work, regardless of the original belief.